|
Market Closed -
Nasdaq
21:00:00 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 22.96 USD | -2.30% |
|
-0.99% | -50.41% |
| 10-19 | Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million | MT |
| 10-09 | Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says | MT |
Company Valuation: Collegium Pharmaceutical, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 765.1 | - | - |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -47.73% | - | - |
| Enterprise Value (EV) | 650 | 778.9 | 1,004 | 924 | 1,464 | 765.1 | 765.1 | 765.1 |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -47.73% | 0% | 0% |
| P/E | 10x | -31.4x | 23.9x | 15.4x | 26.8x | 21x | 6.58x | 4.78x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0.3x | -3.83x | -0.6x | 0x | 0.1x |
| Capitalization / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 0.92x | 0.91x | 0.9x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.92x | 0.91x | 0.9x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 1.71x | 1.85x | 2.04x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 1.7x | 1.9x | 2.03x |
| EV / FCF | - | - | 0x | 0x | 0x | 2.72x | 2.13x | 1.94x |
| FCF Yield | - | - | 27.3% | 22% | 22.4% | 36.8% | 46.9% | 51.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 | 1.117 | 3.573 | 4.915 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 276.9 | 463.9 | 566.8 | 631.4 | 780.6 | 833.1 | 844.5 | 849.1 |
| EBITDA 1 | 118.3 | 266 | 367 | 401.2 | 460.5 | 447.9 | 413.7 | 375.1 |
| EBIT 1 | 17.63 | 33.32 | 167 | 169.9 | 179.6 | 448.9 | 402.1 | 376.5 |
| Net income 1 | 71.52 | -25 | 48.16 | 69.19 | 62.87 | 28.73 | 83.33 | 152.7 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 18.68 | 23.20 | 30.78 | 28.65 | 46.30 | 23.50 | 23.50 | 23.50 |
| Nbr of stocks (in thousands) | 34,797 | 33,572 | 32,611 | 32,250 | 31,611 | 32,556 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.04x | - | - | - | 746M | |
| 37.7x | 13.43x | 28.51x | 0.52% | 1,165B | |
| 39.17x | 6.59x | 18.54x | 1.99% | 645B | |
| 36.4x | 8.37x | 17.27x | 2.41% | 504B | |
| 20.97x | 5.15x | 12.78x | 2.55% | 380B | |
| 107.33x | 5.99x | 25.72x | 2.31% | 363B | |
| 21.95x | 5.71x | 14.04x | 2.79% | 297B | |
| 22.67x | 4.58x | 13.09x | 1.93% | 269B | |
| 28.38x | 7.14x | 12.79x | 2.26% | 237B | |
| -45.82x | 7.02x | 27.23x | 2.1% | 195B | |
| Average | 28.98x | 7.11x | 18.89x | 2.1% | 405.62B | |
| Weighted average by Cap. | 35.73x | 8.44x | 20.74x | 1.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- COLL Stock
- Valuation Collegium Pharmaceutical, Inc.
Select your edition
All financial news and data tailored to specific country editions
